{"nct_id":"NCT03384654","title":"A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"COMPLETED","status_verified_date":"2025-05","start_date":"2018-05-14","start_date_type":"ACTUAL","primary_completion_date":"2022-09-22","primary_completion_date_type":"ACTUAL","completion_date":"2022-09-27","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["JNJ"]}